Androgen Receptor Ligand-Binding Domain Interaction and Nuclear Receptor Specificity of FXXLF and LXXLL Motifs as Determined by L/F Swapping
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) ligand-binding domain (LBD) binds FXXLF motifs, present in the AR N-terminal domain and AR-specific cofactors, and some LXXLL motifs of nuclear receptor coactivators. We demonstrated that in the context of the AR FXXLF motif many different amino acid residues at positions +2 and +3 are compatible with strong AR LBD interaction, although a preference for E at +2 and K or R at +3 was found. Pairwise systematic analysis of F/L swaps at +1 and +5 in FXXLF and LXXLL motifs showed: 1) F to L substitutions in natural FXXLF motifs abolished AR LBD interaction; 2) binding of interacting LXXLL motifs was unchanged or increased upon L to F substitutions; 3) certain noninteracting LXXLL motifs became strongly AR-interacting FXXLF motifs; whereas 4) other nonbinders remained unaffected by L to F substitutions. All FXXLF motifs, but not the corresponding LXXLL motifs, displayed a strong preference for AR LBD. Progesterone receptor LBD interacted with some FXXLF motifs, albeit always less efficiently than corresponding LXXLL motifs. AR LBD interaction of most FXXLF and LXXLL peptides depended on classical charge clamp residue K720, whereas E897 was less important. Other charged residues lining the AR coactivator-binding groove, K717 and R726, modulated optimal peptide binding. Interestingly, these four charged residues affected binding of individual peptides independent of an F or L at +1 and +5 in swap experiments. In conclusion, F residues determine strong and selective peptide interactions with AR. Sequences flanking the core motif determine the specific mode of FXXLF and LXXLL interactions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Instead, it preferentially binds to a FXXLF motif existing in the AR NTD (Dubbink et al., 2006; Dubbink et al., 2004; He et al., 2004).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Dubbink et al., 2006
In the citing paper
“It prefers binding to the FXXLF sequence present in the NTD in contrast to what was seen with the ERα LBD (Dubbink et al., 2006; He et al., 2004; Hsu et al., 2003; Hur et al., 2004).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Dubbink et al., 2006
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Dubbink et al., 2006
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Improved method for high efficiency transformation of intact yeast cells
Gietz, D., Jean, A. S., Woods, R. A., & Schiestl, R. H. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.6.1425 · Cited by 3,261
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
Androgen Receptor Defects: Historical, Clinical, and Molecular Perspectives*
QUIGLEY, C. A., BELLIS, A. D., MARSCHKE, K. B., EL-AWADY, M. K., WILSON, E. M., & FRENCH, F. S. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-271 · Cited by 1,447
The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., & Rosenfeld, M. G. (1997) · Nature · doi:10.1038/42652 · Cited by 1,283
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Cited by
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Self-citationIdentification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
Zhou, X. E., Suino-Powell, K. M., Li, J., He, Y., MacKeigan, J. P., Melcher, K., Yong, E.-L., & Xu, H. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085779 · Cited by 106
Molecular biology of androgen insensitivity
Jääskeläinen, J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.006 · Cited by 110
“On the other hand, binding of proteins to the cofactor-binding groove might affect binding of the ligand (Dubbink et al., 2006).”
Messner, E. A., Steele, T. M., Tsamouri, M. M., Hejazi, N., Gao, A. C., Mudryj, M. M., & Ghosh, P. (2020) · Biomedicines · doi:10.3390/biomedicines8100422 · Cited by 99
“It can also bind so e LXXLL otifs of coactivators [36].”
BackgroundBeyond the Ligand-Binding Pocket: Targeting Alternate Sites in Nuclear Receptors
Caboni, L., & Lloyd, D. G. (2012) · Medicinal Research Reviews · doi:10.1002/med.21275 · Cited by 67
van de Wijngaart, D. J., Molier, M., Lusher, S. J., Hersmus, R., Jenster, G., Trapman, J., & Dubbink, H. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039958 · Cited by 65
Self-citationHsu, C.-L., Liu, J.-S., Wu, P.-L., Guan, H., Chen, Y., Lin, A.-C., Ting, H., Pang, S., Yeh, S.-D., Ma, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.009 · Cited by 58
“Studies of the first (þ1) and the fifth (þ5) amino acid positions of the FxxLFmotif indicate that these residues are involved inmediating high affinity and specific interactions with the AR ligand-binding domain (LBD) (Dubbink et al., 2006).”
BackgroundKollara, A., & Brown, T. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1000-y · Cited by 58
“Evidence that the FXXLF motif of NcoA4 is essential for NcoA4–AR and NcoA4–PR interactions has been provided by site-directed mutagenesis studies [25, 26, 28].”
Methodvan de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Trapman, J., & Jenster, G. W. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0280 · Cited by 55
“From this low number it is again clear that the three core residues of FxxLF-like motifs are not the sole interaction determinants (24, 32, 42).”
Self-citationRegulation of Androgen-Responsive Transcription by the Chromatin Remodeling Factor CHD8
Menon, T., Yates, J. A., & Bochar, D. A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0421 · Cited by 49
Multiple Binding Modes between HNF4α and the LXXLL Motifs of PGC-1α Lead to Full Activation
Rha, G. B., Wu, G., Shoelson, S. E., & Chi, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052506 · Cited by 46
Steroid receptor/coactivator binding inhibitors: An update
Skowron, K. J., Booker, K., Cheng, C., Creed, S. M., David, B. P., Lazzara, P. R., Lian, A., Siddiqui, Z., Speltz, T. E., & Moore, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110471 · Cited by 41
“Additionally, through comparison of binding experiments involving peptide interaction with AR and ERα LBDs, the authors determined that the shape of a NR coactivator binding groove can be critical to selective peptide interaction, with the FXXLF motif being specific for AR rather than ERα due to the AR’s deeper hydrop…”
BackgroundInfluentialLucki, N. C., Li, D., Bandyopadhyay, S., Wang, E. L., Merrill, A. H., & Sewer, M. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00378-12 · Cited by 31
“Generally, coregulators bind to the AF-1 and/or AF-2 domains of nuclear receptors through LXXLL motifs (nuclear receptor [NR] boxes), where X is any amino acid and L is a leucine (22, 44).”
BackgroundInfluentialSong, C.-H., Lee, H. J., Park, E., & Lee, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049026 · Cited by 25
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer
Annala, M., Kivinummi, K. K., Tuominen, J. I., Karakurt, S., Granberg, K. J., Latonen, L., Ylipää, A., Sjöblom, L., Ruusuvuori, P., Saramäki, O. R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3359 · Cited by 25
Kraus, K., KLEENE, R. B., Henis, M., Braren, I., Kataria, H., Sharaf, A. L., Loers, G., Schachner, M., & Lutz, D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0901-7 · Cited by 24
The androgen receptor messenger RNA: what do we know?
Likos, E., Bhattarai, A., Weyman, C. M., & Shukla, G. C. (2022) · RNA Biology · doi:10.1080/15476286.2022.2084839 · Cited by 31
Stoyanova, I. I., & Lutz, D. (2022) · Cells · doi:10.3390/cells11193085 · Cited by 25
Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Leclercq, G., Gallo, D., Cossy, J., Laïos, I., Larsimont, D., Laurent, G., & Jacquot, Y. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797416048 · Cited by 23
Ertl, I. E., Brettner, R., Kronabitter, H., Mohr, T. T., Derdak, S. V., Jeitler, M., Bilban, M., Garstka, N., & Shariat, S. F. (2022) · Cells · doi:10.3390/cells12010124 · Cited by 22
“Since all SMARCD proteins contain FxxFF and LxxLL motifs that mediate direct interactions with AR, we hypothesized that SMARCD2 and SMARCD3 also act as AR-cofactors [17,44].”
BackgroundAntagonizing the Androgen Receptor with a Biomimetic Acyltransferase
Zhang, Y., Mantravadi, P. K., Jobbagy, S., Bao, W., & Koh, J. T. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00659 · Cited by 20
Androgen Receptor in Hormone Receptor-Positive Breast Cancer
Khan, A. F., Karami, S., Peidl, A. S., Waiters, K. D., Babajide, M. F., & Bawa‐Khalfe, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010476 · Cited by 16
“The LBD has been shown to bind coregulators that contain either FXXLF or LXXLL motifs; several studies indicate a preference for FXXLF-containing coregulators supported with the greater stability of an N-terminus to C-terminus interaction [52,53].”
BackgroundThe role of cofactors in sex steroid action
Trapman, J., & Dubbink, H. J. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.002 · Cited by 15
Self-citationvan de Wijngaart, D. J., Dubbink, H. J., Molier, M., de Vos, C., Jenster, G. W., & Trapman, J. (2011) · The Prostate · doi:10.1002/pros.21238 · Cited by 13
“Although FxxLF motifs preferentially bind AR, some FxxLF motifs, including the FxxLF motif in ARA70, also bind PR [31,40].”
BackgroundSelf-citationLiang, J., Wang, D., Wu, Y., Shi, J., Xie, B., Xiao, R., Ni, J., Wang, C., Dong, C., Shu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00425 · Cited by 12
Ding, Z., Shen, J. Y., Hong, J. W., Zhang, R., Li, Z., Wang, Q., Zhang, J. P., Zhang, M. R., & Xu, L. (2020) · PubMed · doi:10.3967/bes2020.022 · Cited by 13
Ahmad, A., Makhmutova, Z., Cao, W., Majaz, S., Amin, A., & Xie, Y. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2179035 · Cited by 10
“Among them, the LYRL motif containing an epitope of 9 residues revealed the importance of L452 of the spike RBD HLA [38].”
BackgroundInfluentialElfferich, P., Juniarto, A. Z., Dubbink, H. J., van Royen, M. E., Molier, M., Hoogerbrugge, J. W., Houtsmuller, A. B., Trapman, J., Santosa, A., de Jong, F. H., et al. (2009) · Sexual Development · doi:10.1159/000252814 · Cited by 9
Self-citationZakharov, M. N., Pillai, B. K., Bhasin, S., Ulloor, J., Istomin, A. Y., Guo, C., Godzik, A., Kumar, P., & Jasuja, R. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.03.003 · Cited by 12
“…those containing FxxLF and those containing LxxLL motifs (Zhou et al., 2002; Bevan et al., 1999; Estebanez-Perpina et al., 2005; Chang and McDonnell, 2002; He and Wilson, 2003; Askew et al., 2007; van de Wijngaart et al., 2006; Dubbink et al., 2006; He et al., 1999, 2001, 2002; Hur et al., 2004).”
BackgroundElfferich, P., van Royen, M. E., van de Wijngaart, D. J., Trapman, J., Drop, S. L. S., van den Akker, E. L. T., Lusher, S. J., Bosch, R., Bunch, T., Hughes, I. A., et al. (2013) · Sexual Development · doi:10.1159/000351820 · Cited by 10
“…with hormone, the ARLBD is folded as a sandwich of 11 α-helices and 2 antiparallel β-strands, resulting in a hydrophobic groove that interacts with LxxLL- and FxxLF-like motifs present in AR coregulators and also in the AR-NTD [He et al., 2000; Steketee et al., 2002; Dubbink et al., 2006].”
BackgroundSelf-citationFancher, A. T., Hua, Y., Strock, C. J., & Johnston, P. A. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2019.940 · Cited by 8
“It has been reported that the LXXLL motif from box III of the TIF2 NID contributes most of the binding interactions with the AR AF-2 surface.(37,39,56,57) In our assay, the histidine-tagged AR-LBD protein was”
BackgroundRoles of Key Epigenetic Regulators in the Gene Transcription and Progression of Prostate Cancer
Deng, T., Xiao, Y., Dai, Y., Xie, L. Y., & Li, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.743376 · Cited by 10
“LBD interacts with NTD or other specific cofactors through the FXXLF motif to regulate gene transcription (Dubbink et al., 2006; Messner et al., 2020).”
Background165 Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer
Annala, M., Kivinummi, K. K., Tuominen, J., Latonen, L., Ylipää, A., Saramäki, O. R., Kaukoniemi, K. M., Karakurt, S., Yli-Harja, O. P., Vessella, R. L., et al. (2015) · European Urology Supplements · doi:10.1016/s1569-9056(15)60167-1 · Cited by 6
Nguyen, T. H., Nguyen, D. Q., Kim, L. N. T., Thi, T. N. N., Nguyen, T. P. M., Tran, N. D., & Hoàng, N. H. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01249-6 · Cited by 4
Fancher, A. T., Hua, Y., Close, D. A., Xu, W., McDermott, L. A., Strock, C. J., Santiago, U., Camacho, C. J., & Johnston, P. A. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.08.001 · Cited by 4
“The LXXLL motifs of p160/SRC CoAs mediate binding to the AF-2 surface of AR resulting in activation of gene transcription [30,36–38].”
Selecting the Right Targets for Cancer Therapy
Bronchud, M. H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_1 · Cited by 6
Helszer, Z., Dmochowska, A., Borkowska, E. M., Moczulska, H., Słowikowska‐Hilczer, J., Pietrusiński, M., Jędrzejczyk, S., & Kałużewski, B. (2013) · Endokrynologia Polska · doi:10.5603/ep.2013.0023 · Cited by 4
“Furthermore, binding of proteins to the cofactor-binding groove might affect binding of the ligand [11].”
BackgroundYun, S., & Park, J. (2020) · Journal of International Medical Research · doi:10.1177/0300060520919236 · Cited by 3
Targeting the Nuclear Receptor–Cofactor Interaction
Vaz, B., Möcklinghoff, S., & Brunsveld, L. (2008) · Methods and principles in medicinal chemistry · doi:10.1002/9783527623297.ch2 · Cited by 4
Song, T.-Q., & Li, J. (2019) · Current Computer - Aided Drug Design · doi:10.2174/1573409915666190502153307 · Cited by 2
“Studies of the first (+1) and the fifth (+5) amino acid positions of the FxxLF motif indicate that these residues are involved in mediating high affinity and specific interactions with the AR ligand-binding domain [13].”
Trapman, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_16 · Cited by 1
“Complementary data came from F/L swapping experiments of FxxLF and LxxLL-based peptide motifs (Dubbink et al. 2006).”
BackgroundMethodInfluentialSelf-citationReptides and Proteins Interacting with the Androgen Receptor
van de Wijngaart, D. J. (2009)
Modulation of Androgen Receptor Transcriptional Activity
Wong, H. Y. (2009) · RePub (Erasmus University Rotterdam) · Cited by 1
Targeting alpha-helix based protein interactions; nuclear receptors as a case study
Milroy, L. ‐., Nieto, L., & Brunsveld, L. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734677-00238 · Cited by 1
Molecular mechanisms of androgen receptor functions
Steketee, K. (2007) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
Dziubańska-Kusibab, P. J., Jourdan, T., & Haendler, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188200
“Mapping of the domains involved in the interaction of the AR with associated proteins has been successful in several cases, but disrupting these contacts remains challenging [117,144,145].”
Metadata
- Authors
- Dubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J.
- Affiliations
- Erasmus MC (NL)
- Departments of Pathology (H.J.D., R.H., M.M., J.T.), 3000 DR Rotterdam, The Netherlands;
- University of York (GB)
- Urology (G.J.), 3000 DR Rotterdam, The Netherlands;
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2006-08-01
- Volume
- 20
- Issue
- 8
- Pages
- 1742-1755
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2126628258
- Cited by
- 47
- References
- 43
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 5
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- androgen receptor, ligand-binding domain, LXXLL motif, nuclear receptor coactivators, peptide binding specificity, progesterone receptor, charged residues
- MeSH terms
- Binding Sites, Cells, Cultured, DNA Mutational Analysis, Humans, Leucine, Ligands, Models, Molecular, Peptides, Phenylalanine, Protein Binding, Protons, Receptors, Androgen, Transcription Factors, Transfection, Leucine Zippers, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Receptors, Cytoplasmic and Nuclear, Dimerization, Two-Hybrid System Techniques, Amino Acid Motifs, Protein Interaction Mapping, Histone Acetyltransferases, Nuclear Receptor Coactivator 2, Nuclear Receptor Coactivator 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.